CAJ | 학술논문

目的：探讨抗病毒治疗对失代偿期乙型肝炎肝硬化患者临床效果及对病程进展的影响。方法：77例失代偿期乙型肝炎肝硬化患者随机分成治疗组（39例）和对照组（38例），治疗组服用阿德福韦酯10m g/d进行抗病毒治疗，同时给予常规综合护肝对症治疗；对照组仅给予常规综合护肝对症治疗，随访时间为（36士3）个月。结果：两组死亡率分别为7.7%和15.7%(P<0.05)，肝癌发生率分别为2.6%和2.6%(P>0.05)。治疗后child-Pugh评分下降>2分的患者比率分别为89.2%和62.4%(P<0.05)，HBV-DNA转阴率分别为84.6%和13.2%(P<0.01)。结论：对失代偿期肝硬化患者进行抗病毒治疗可以抑制乙肝病毒复制，肝功能得到改善，可延缓病情进展，延长患者生命。
목적：탐토항병독치료대실대상기을형간염간경화환자림상효과급대병정진전적영향。방법：77례실대상기을형간염간경화환자수궤분성치료조（39례）화대조조（38례），치료조복용아덕복위지10m g/d진행항병독치료，동시급여상규종합호간대증치료；대조조부급여상규종합호간대증치료，수방시간위（36사3）개월。결과：량조사망솔분별위7.7%화15.7%(P<0.05)，간암발생솔분별위2.6%화2.6%(P>0.05)。치료후child-Pugh평분하강>2분적환자비솔분별위89.2%화62.4%(P<0.05)，HBV-DNA전음솔분별위84.6%화13.2%(P<0.01)。결론：대실대상기간경화환자진행항병독치료가이억제을간병독복제，간공능득도개선，가연완병정진전，연장환자생명。
Objective: To investigate the clinical effect and impact on progression in patients with anti-viral therapy for decompensated cirrhosis . Methods: 77 cases of decompensated cirrhosis patients were randomly divided into treatment group (39 cases) and control group (38 cases), the treatment group taking adefovir dipivoxil 10mg / d for anti-viral treatment, while giving the routine liver symptomatic treatment; control group were given the routine liver symptomatic treatment, folow-up time was (36 ± 3) months. Results: Two mortality rates were 7.7% and 15.7% (P <0.05), liver cancer incidence was 2.6% and 2.6% (P > 0.05). After treatment, child-Pugh score decreased> 2 points patient ratios were 89.2% and 62.4% (P <0.05), HBV-DNA negative rates were84.6% and 13.2% (P <0.01).Conclusion: Patients with decompensated cirrhosis antiretroviral therapy can suppress HBV replication, liver function improved, can delay disease progression and prolong the lives of patients.